New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
07:59 EDTOHRPOhr Pharmaceutical negative report was misleading, says Brean Capital
Brean Capital believes last week's negative report on Ohr Pharmaceuticals was misleading. The firm believes its squalamine eye drops will be effective and expects the company to enter a joint venture to further develop it trodusquemine drug for yet undisclosed new indications. Shares are Buy rated with a $21 price target.
News For OHRP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
10:00 EDTOHRPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:22 EDTOHRPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Amira Nature Foods (ANFI), up 8.6%... Stratasys (SSYS), up 3.6%... Magnum Hunter (MHR), up 3%. ALSO HIGHER: Mavenir Systems (MVNR), up 19.1% after Mitel (MITL) agrees to acquire Mavenir Systems for $560M... Athersys (ATHX), up 19.7% following license agreement and collaboration with Chugai... OHR Pharmaceutical (OHRP), up 11.4% following additional positive data from OHR-102 IMPACT study... NXP Semiconductors (NXPI), up 14% following merger agreement with Freescale Semiconductor (FSL). Freescale Semiconductor is up 9.1%... Mast Therapeutics (MSTX), up 7.7% following positive results from Vepoloxamer study. DOWN AFTER EARNINGS: JinkoSolar (JKS), down 4.7%... Scorpio Tankers (STNG), down 4.5%. ALSO LOWER: Lumber Liquidators (LL), down 24.2% following CBS' 60 Minutes says that the company is linked to health and safety violations... Aruba Networks (ARUN), down 1.7% after HP (HPQ) confirms deal to acquire Aruba Networks for $24.67... Pacira Pharmaceuticals (PCRX), down 14.4% after receiving complete response letter from FDA for sNDA in use of Exparel... 500.com (WBAI), down 14.4% after announcing that temporary suspension will adversely impact financial results.
07:59 EDTOHRPOhr Pharmaceutical announces additional positive data from OHR-102 IMPACT study
Subscribe for More Information
07:47 EDTOHRPOhr Pharmaceutical initiated with an Outperform at Cowen
Subscribe for More Information
February 26, 2015
08:19 EDTOHRPOhr Pharmaceutical appoints Avner Ingerman, M.D. as Chief Clinical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use